High mobility group box-containing protein 4 (HMGXB4)

High mobility group box-containing protein 4 (HMGXB4) is a mammal-specific, nonhistone chromosomal protein belonging to the high mobility group (HMG) family[1][3]. It has a single HMG box domain and is almost exclusively localized in the nucleus, where it modulates chromatin structure and enhances the transcription of key proinflammatory genes by binding to enhancer regions, particularly in response to inflammatory stimuli such as bacterial lipopolysaccharide (LPS)[1][3]. HMGXB4 expression is increased during inflammation, supporting the induction of genes such as NOS2 (inducible nitric oxide synthase) and ICAM1, which promote nitric oxide production and monocyte-endothelial adhesion, respectively, contributing to tissue damage in conditions like septic shock[1]. Deletion of HMGXB4 in mice has been shown to ameliorate endotoxin-induced mortality and vascular injury, suggesting a potential therapeutic angle for targeting this factor in inflammatory diseases[1]. At present, no direct drugs or specific therapeutic inhibitors are reported for HMGXB4. HMGXB4 is mechanistically and structurally distinct from other HMGB proteins, as it does not contain the typical acidic tail and has only one HMG box domain[1][3]. It mainly functions as a chromatin architectural protein and possible transcription cofactor, not a classical transcription factor with sequence-specific DNA binding[1]. There are no approved or experimental drugs known to selectively target HMGXB4, nor is there evidence for its use as a clinical biomarker, although its expression marks heightened inflammation[1][3].

Other names

HMGXB4HMG2L1HMGBCGTHC211630P53NHMG box-containing protein 4High mobility group protein 2-like 1Protein HMGBCGHMG domain-containing protein 4HMG box domain containing 4

Not applicable yet (no known drugs directly target HMGXB4 as of current knowledge)